KRAS and colorectal carcinoma: Since regression of KRAS mutations has been reported in oligometastatic CRC patients, we explored NKs and CD8s from peripheral blood of oligometastatic patients for cytotoxic activity against CRC cells through CD107a-externalization (lysosomal protein LAMP-1-based degranulation assay) (Figure 4).